AKRO vs. VRNA, PCRX, XNCR, GMTX, ABCL, LGND, DCPH, IRWD, DAWN, and KNSA
Should you be buying Akero Therapeutics stock or one of its competitors? The main competitors of Akero Therapeutics include Verona Pharma (VRNA), Pacira BioSciences (PCRX), Xencor (XNCR), Gemini Therapeutics (GMTX), AbCellera Biologics (ABCL), Ligand Pharmaceuticals (LGND), Deciphera Pharmaceuticals (DCPH), Ironwood Pharmaceuticals (IRWD), Day One Biopharmaceuticals (DAWN), and Kiniksa Pharmaceuticals (KNSA). These companies are all part of the "pharmaceutical preparations" industry.
Akero Therapeutics (NASDAQ:AKRO) and Verona Pharma (NASDAQ:VRNA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, community ranking, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.
Akero Therapeutics presently has a consensus target price of $39.00, suggesting a potential upside of 80.56%. Verona Pharma has a consensus target price of $33.60, suggesting a potential upside of 104.88%. Given Verona Pharma's higher possible upside, analysts clearly believe Verona Pharma is more favorable than Akero Therapeutics.
In the previous week, Verona Pharma had 4 more articles in the media than Akero Therapeutics. MarketBeat recorded 5 mentions for Verona Pharma and 1 mentions for Akero Therapeutics. Akero Therapeutics' average media sentiment score of 1.91 beat Verona Pharma's score of 0.53 indicating that Akero Therapeutics is being referred to more favorably in the media.
85.9% of Verona Pharma shares are held by institutional investors. 9.7% of Akero Therapeutics shares are held by insiders. Comparatively, 4.8% of Verona Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Verona Pharma received 214 more outperform votes than Akero Therapeutics when rated by MarketBeat users. Likewise, 79.90% of users gave Verona Pharma an outperform vote while only 61.15% of users gave Akero Therapeutics an outperform vote.
Verona Pharma has higher revenue and earnings than Akero Therapeutics. Verona Pharma is trading at a lower price-to-earnings ratio than Akero Therapeutics, indicating that it is currently the more affordable of the two stocks.
Akero Therapeutics has a beta of -0.38, indicating that its stock price is 138% less volatile than the S&P 500. Comparatively, Verona Pharma has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500.
Verona Pharma's return on equity of -20.47% beat Akero Therapeutics' return on equity.
Summary
Verona Pharma beats Akero Therapeutics on 11 of the 15 factors compared between the two stocks.
Get Akero Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AKRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akero Therapeutics Competitors List
Related Companies and Tools
